Non-medical switching negatively impacts patients by disrupting their care and does not generate cost savings for the patient or the insurer.
We believe that CMS must exempt diabetes testing supplies from the CBP until they can employ transparent, scientific-based methodologies for monitoring the safety of patients and ensuring adequate access to supplies.
These programs prevent people from diabetes from using a manufacturer’s copay assistance card— coupons provided to patients to cover high copays on brand name and specialty drugs — toward their annual deductible.
